Knowledge HQ

All
Publications

Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients

This study identifies an HLA-A*11:01-restricted TCR targeting KRAS G12V from a pancreatic cancer patient. T cells engineered with this TCR were expanded in G-Rex 24-well plates and showed specific recognition of tumor organoids, enhanced by IFN-gamma priming.
Download Now
Publications

Donor Variability and PD-1 Expression Limit BK Polyomavirus-specific T-cell Function and Therapy

This study compares conventional and G-Rex systems for expanding BKPyV-specific T cells. G-Rex cultures resulted in higher total cell counts but increased PD-1 expression. The study highlights the need for optimization in adoptive T-cell therapy protocols for BKPyV.
Download Now
Publications

Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor That Unleashes PD-1 Checkpoint and CAR T-Cell Immunotherapies

This paper reports on BMS-986408, a dual DGK inhibitor that enhances PD-1 and CAR-T therapies. It improves T-cell signaling and effector function. CAR T cells were expanded in G-Rex 6M well plates during the manufacturing process for experimental assays.
Download Now
Publications

Autologous Monocyte-Derived Dendritic Cells (MoDC) Manufactured in the Same Device as Antigen Presenting Cells (APC) for the Production of Tumor-Associated Antigen-Specific T Cells (TAAT) in the Same Device

This study demonstrates a process to manufacture Tumor-Associated Antigen-Specific T Cells (TAAT) by priming naïve T cells with MoDC directly in G-Rex devices. This closed-system approach eliminates the need for MoDC harvest and restimulation, yielding clinical doses from small blood volumes.
Download Now
Publications

Autologous Monocyte-Derived Dendritic Cells (MoDC) Manufactured in the Same Device as Antigen Presenting Cells (APC)

This abstract describes a streamlined protocol for manufacturing Monocyte-Derived Dendritic Cells (MoDC) using G-Rex devices. The method reduces cell loss associated with harvesting adherent cells and allows for the subsequent production of Tumor-Associated Antigen-Specific T Cells (TAAT) in the same vessel.
Download Now
Publications

MARC, a novel modular chimeric antigen receptor, improves T cell- based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence

This study presents MARC, a modular CAR design that mimics native receptors to prevent tonic signaling and exhaustion. Primary T cells were transduced and expanded in 24-well G-Rex plates, demonstrating improved persistence and efficacy in leukemia models compared to traditional CARs.
Download Now
Publications

Efficient nonviral integration of large transgenes into human T cells using Cas9-CLIPT

This paper introduces Cas9-CLIPT, a method for efficient non-viral CRISPR-Cas9 knock-in of large transgenes (like CARs) into T cells. G-Rex 6M well plates were used for the expansion of CAR T cells during the manufacturing process, supporting clinical scalability.
Download Now
Publications

PRDM1 Is a Key Regulator of the NKT-cell Central Memory Program and Effector Function

This study identifies PRDM1 as a key regulator of NKT cell central memory and effector function using CRISPR screening. PRDM1 knockdown preserved cytotoxicity and memory phenotype. NKT cells were expanded and restimulated in 6-well G-Rex plates during the protocol.
Download Now
Publications

Optimization of Transduction step

This poster describes a simplified CAR-T manufacturing method (Spo-T) using RetroNectin-coated G-Rex vessels. This approach allows simultaneous T-cell activation and transduction in a single vessel, showing higher proliferation and stemness compared to conventional methods.
Download Now
Publications

CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma

This study identifies CSF1R+ myeloid-monocytic (LAMM) cells as drivers of CAR-T resistance in B-NHL. CSF1R inhibition combined with CAR-T therapy enhanced efficacy. Author H. Balke-Want received funding from the G-Rex Grant Program (Wilson Wolf), though specific device usage for main data is not detailed.
Download Now
Publications

Allogeneic Polyclonal CD38KO/CD38-CAR γδT Cells For The Treatment Of T Cell Malignancies

This study develops CD38KO/CD38-CAR γδT cells to treat T-cell malignancies, avoiding fratricide. A hybrid expansion protocol using G-Rex plates allowed robust expansion of polyclonal γδT cells. The edited cells showed potent anti-tumor activity in vitro and in vivo against T-ALL.
Download Now
Publications

Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33 and tEGFR suicide gene system

This study describes T cells engineered with five genes (WT1-TCR, NFAT-GMCAR, CD33 BiTE, tEGFR) to target AML. G-Rex plates were used for co-culture assays with primary AML cells and bone marrow to evaluate cytotoxicity and safety. The strategy enhances anti-tumor potency and provides a safety switch.
Download Now

ScaleReady is a joint venture between Wilson Wolf Manufacturing and Bio-Techne.